NCT03528629View on ClinicalTrials.gov

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

June 9, 2020

Study Completion Date

June 9, 2020

Conditions
Gastric CancerGastro-esophageal Junction (GEJ) Cancer
Interventions
DRUG

Zolbetuximab

Zolbetuximab will be administered as a 2-hour intravenous infusion.

Trial Locations (1)

Unknown

Site JP00001, Kashiwa

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY